Documents

Q1 2026 results surpassed expectations, prompting raised full-year EBITDA and EPS guidance.

Operational focus shifts to filling new beds, managing policy headwinds, and reducing debt.

Organizational changes and cost controls aim to boost growth as CapEx drops and debt reduction takes priority.

2026 growth hinges on ramping new beds, operational discipline, and improved cash flow.

Bed expansion, quality initiatives, and technology investments set the stage for future growth.

2026 guidance targets revenue growth, lower CapEx, and operational focus amid regulatory headwinds.

Litigation settled, growth driven by new beds and JVs, with 2026 positioned for strong earnings.

Revenue up, EBITDA down; guidance cut, CapEx slashed, and portfolio optimized with closures.

CapEx cuts, facility closures, and tech investments set the stage for growth and cash flow in 2026.

Revenue up 9.2% and Adjusted EBITDA up 7.5%, with Medicaid volumes under pressure.

Strong demand and record bed growth drive steady financial performance and expansion.

Q1 results met expectations, with robust expansion and reaffirmed growth outlook for 2025.

Growth targets recalibrated for balance, with 8% revenue guidance and focus on de novo expansion.

Malpractice costs, moderated CapEx, and slower bed growth shape outlook; cash flow positive by 2026.

Facility expansion and tech investments drive growth amid high demand and operational challenges.

Revenue up 7.7% and net income rebounded as Acadia expanded and resolved major litigation.